canagliflozin + hydrochlorothiazide

Canagliflozin + hydrochlorothiazide is a combination of two oral pharmaceutical agents used primarily for the management of type 2 diabetes mellitus and hypertension. Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that lowers blood glucose by preventing renal reabsorption of glucose, leading to increased urinary glucose excretion[1][4][5]. Hydrochlorothiazide is a thiazide diuretic that reduces blood pressure by inhibiting sodium reabsorption in the distal tubules of the kidney, resulting in increased excretion of sodium and water. The combination may be considered for patients who require both glycemic control and antihypertensive therapy. Canagliflozin also has demonstrated benefits in reducing cardiovascular events and slowing progression of diabetic kidney disease in patients with type 2 diabetes[1][4][5]. This combination increases diuretic effects, which may raise risks such as dehydration or hypotension[2].